U.S. Media Stock News

NYSE:WKC
NYSE:WKCOil and Gas

A Look At World Kinect's Valuation As Q1 Strength And 2026 EPS Upgrade Renew Investor Interest

World Kinect (WKC) has returned to focus after Q1 results reflected stronger profits in its marine and aviation segments, alongside a $75 million share repurchase and a higher full-year 2026 adjusted EPS outlook. See our latest analysis for World Kinect. The Q1 beat and higher 2026 guidance appear to be feeding into price momentum, with a 1 month share price return of 20.19% and a year to date share price return of 16.25% against a more modest 1 year total shareholder return of 4.90%. This...
NYSE:GEV
NYSE:GEVElectrical

Is It Too Late To Consider GE Vernova (GEV) After Its 156% One Year Surge?

Wondering if GE Vernova at US$1,090.53 is still offering value after a strong run, or if you are turning up late to the story. The stock has logged returns of 4.3% over the past week, 10.4% over the past month, 60.5% year to date and 156.0% over the last year, which naturally raises questions about how the current price lines up with underlying value. Recent coverage has focused on GE Vernova as a pure play in the capital goods space following its separation from General Electric, with...
NasdaqGS:TROW
NasdaqGS:TROWCapital Markets

Assessing T. Rowe Price Group (TROW) Valuation After Recent Share Price Momentum

Recent performance snapshot T. Rowe Price Group (TROW) has recently drawn investor attention after a period where the stock is up about 7% over the past month and roughly 9% in the past 3 months. See our latest analysis for T. Rowe Price Group. At a share price of $102.41, T. Rowe Price Group has a 30 day share price return of 6.86% and a 1 year total shareholder return of 10.54%. This suggests recent momentum contrasts with weaker longer term results such as the 5 year total shareholder...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

Encaleret NDA, Acoramidis Progress, and Buyback Could Be A Game Changer For BridgeBio (BBIO)

In early May 2026, BridgeBio Pharma reported strong new clinical and regulatory progress, including FDA submission of encaleret for ADH1 and additional Phase 3 data for acoramidis (Attruby/BEYONTTRA) in transthyretin amyloid cardiomyopathy, alongside higher quarterly revenue and a newly authorized US$500,000,000 share repurchase program. The combination of compelling late-stage trial readouts, expanding global approvals for acoramidis, and an NDA for encaleret underscores BridgeBio’s push to...
NYSE:ETN
NYSE:ETNElectrical

Eaton (ETN) Valuation In Focus As AI Data Center Demand, NVIDIA Deal And New Investment Lift Optimism

Eaton (ETN) is back in focus after strong first quarter results, updated earnings guidance, and a series of AI focused power infrastructure moves that include a new US$30 million switchgear facility in Nebraska. See our latest analysis for Eaton. The stock has kept its recent momentum going, with a year to date share price return of 24.68% and a 5 year total shareholder return of 207.68%. Eaton's AI centric power projects, Boyd Thermal acquisition and NVIDIA partnership keep it firmly on...
NYSE:NU
NYSE:NUBanks

Nu Holdings (NU) Valuation After Earnings Miss And AI Focused US Banking Expansion

Nu Holdings (NYSE:NU) is back in focus after first quarter 2026 results combined strong reported revenue and net income with misses versus earnings and sales forecasts, alongside fresh progress on AI and U.S. expansion. See our latest analysis for Nu Holdings. At a share price of US$12.93, Nu’s recent momentum has cooled, with the 30 day share price return down 15.77% and the year to date share price return down 24.03%. Even so, the 3 year total shareholder return of 102.35% still reflects a...
NYSE:ABR
NYSE:ABRMortgage REITs

Arbor Realty Trust (ABR) Is Down 28.5% After Dividend Cut And Impairment Losses - Has The Bull Case Changed?

In the first quarter of 2026, Arbor Realty Trust, Inc. reported sales of US$8.06 million, net income of US$10.97 million, and a US$12.50 million impairment loss on real estate owned, while also declaring a reduced quarterly dividend of US$0.17 per share. The combination of lower earnings, sizeable impairment charges, and another dividend reset underscores how prolonged troubles in non-performing loans and real estate owned are pressuring Arbor Realty Trust’s balance sheet and income...
NYSE:MKL
NYSE:MKLInsurance

Markel Expands ProSolutions As Shares Trade Below Valuation Estimates

Markel Group (NYSE:MKL) has expanded its ProSolutions liability portfolio with new Media Shield and Entertainment Shield products. The new offerings bundle professional, cyber, media, and general liability coverage for content creators and entertainment businesses. For investors watching NYSE:MKL, this product launch adds another piece to the broader insurance and services platform the company is building. The stock most recently closed at $1,846.01, with a return of 36.7% over the past 3...
NYSE:KOS
NYSE:KOSOil and Gas

Assessing Kosmos Energy (KOS) Valuation After Record Output And Accelerated Deleveraging

Kosmos Energy (KOS) is back in focus after reporting record first quarter production of about 74,800 boepd, accelerated net debt reduction plans, and progress on its Greater Tortue Ahmeyim and Tiberius projects. See our latest analysis for Kosmos Energy. The recent operational update comes after a steep 228.18% year to date share price return and a 74.40% 90 day share price return, while the 3 year total shareholder return has declined 53.34%. This highlights strong short term momentum...